Overview

COlchicine for the Prevention of Post Electrical Cardioversion Recurrence of AF

Status:
Withdrawn
Trial end date:
2018-09-02
Target enrollment:
Participant gender:
Summary
There is substantial evidence linking inflammation to the initiation and perpetuation of AF. Although the precise mechanism by which inflammation contributes to the development of AF remains unclear, it has been proposed that inflammation may lead to "atrial myocarditis" with subsequent electrical and structural changes involving both atrial myocytes and extracellular matrix, leading finally to initiation and maintenance of AF. The high incidence of AF in post-operative cardiac surgeries, a state of intense inflammatory process, points out this association. Similarly, in non operative AF, inflammation appears to play a prominent role in both etiology and maintenance of AF. Indeed an increase of inflammatory markers to both paroxysmal and persistent AF was shown by numerous studies.
Phase:
Phase 3
Details
Lead Sponsor:
Elpen Pharmaceutical Co. Inc.
Treatments:
Colchicine